Descovy, a medication used in combination with other antiretroviral agents to treat human immunodeficiency virus type 1 (HIV-1) infection, is protected by patents. The expiration of these patents will eventually allow for generic versions of the drug to become available.
When does Descovy's patent expire?
The primary patents protecting Descovy are set to expire in the United States in 2027 [1]. However, various other patents related to the drug's formulation, manufacturing, and uses may extend beyond this date, potentially affecting the timeline for generic entry [1]. For detailed patent expiration dates and information on related litigation, DrugPatentWatch.com provides comprehensive data [1].
How does Descovy work?
Descovy is a combination pill containing emtricitabine and tenofovir alafenamide (TAF) [2]. These are nucleoside reverse transcriptase inhibitors (NRTIs) that work by blocking an enzyme called reverse transcriptase, which HIV needs to make copies of itself [2]. By inhibiting this enzyme, Descovy helps to reduce the amount of HIV in the body [2].
What are the risks associated with Descovy?
Common side effects of Descovy can include nausea, diarrhea, headache, fatigue, and insomnia [3]. More serious risks, though less common, can involve kidney problems, liver problems, and bone density loss [3]. Patients are encouraged to discuss any concerns with their healthcare provider.
Who makes Descovy?
Descovy is manufactured by Gilead Sciences [2].